Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWB-103 for Diabetic Lower Limb Ulcers
NCT03624023Phase 2Completed
- Sponsor
- Transwell Biotech Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Hydrogel Systems, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human acidic fibroblast growth factor in diabetic foot ulcer (DFU), sponsored by Transwell Biotech Co., Ltd. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Dec 2019; status: completed.
02
Drugs
recombinant human acidic fibroblast growth factor
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT03624023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624023.